Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and postmenopausal HR-positive, HER2-negative advanced breast cancer resistant to hormonal therapy

Ovarian highlights from ESMO 2019

Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC

Comment: Immunotherapy combination for advanced NSCLC

More ovarian cancer patients benefit from maintenance combined targeted therapy

Nivolumab plus ipilimumab combination offers chemotherapy-free option for advanced NSCLC

Comment: Nivolumab plus ipilimumab combination for advanced NSCLC

Comparative effectiveness of lenalidomide, bortezomib, and their combinations for elderly myeloma patients

A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple myeloma

Real-world use of carfilzomib therapy among patients with existing cardiovascular medical history

Twice-weekly vs once-weekly Krd in early relapsed refractory multiple myeloma

HORIZON: Melflufen in high risk relapsed refractory multiple myeloma patients with extramedullary disease